We used the antibodies against the following proteins: TSPO (ab109497), AIF1/IBA1 (ab5076), MAP2 (ab5392), and COX4I1 (Ab14744) from Abcam; VIM/vimentin (AB5733), RBFOX3/NeuN (MAB377), and
GFAP (MAB360) from Millipore; NES/nestin (NB100-1604) and NEFM/NFM (NBP2-46,618) from Novus Biologicals; LAMP2 (L0668), MAP1LC3B/LC3B (L8918), SQSTM1 (P0067), and ATG7 (A2856) from Sigma-Aldrich; AGRP (AF634) from R&D Systems; p-PRKAA/p-AMPKα (Thr172, 2535), PRKAA/AMPKα (2532), p-ACAC (Ser79, 3661), ACAC (3662), p-ULK1 (Ser555, 5869), ULK1 (8054), BECN1/Beclin1 (3738), and GAPDH (2118) from Cell Signaling Technology
The following secondary antibodies were used:
Cy3-conjugated anti-rabbit IgG (Jackson ImmunoResearch, 711–165-152),
Alexa488-conjugated anti-rabbit (Thermo Fisher Scientific, A-11,008),
Alexa488-conjugated anti-mouse (Jackson ImmunoResearch, 715–545-150),
Alexa488-conjugated anti-goat (Molecular Probes, A-11,055), Alexa488-conjugated anti-chicken IgG (Jackson ImmunoResearch, 703–545-155). Alexa647-conjugated anti-chicken IgG (Jackson ImmunoResearch, 703–545-155), and
horse radish peroxidase-conjugated anti-rabbit (Thermo Fisher Scientific, NCI460KR)
and anti-mouse (Cell Signaling Technology, 7076) antibodies.
Kim S., Kim N., Park S., Jeon Y., Lee J., Yoo S.J., Lee J.W., Moon C., Yu S.W, & Kim E.K. (2019). Tanycytic TSPO inhibition induces lipophagy to regulate lipid metabolism and improve energy balance. Autophagy, 16(7), 1200-1220.